MONITORING HORMONAL ABLATION OF PROSTATE CANCER BY MRSI

通过 MRSI 监测前列腺癌的激素消融

• 批准号: 6514345
• 负责人: MARK G SWANSON
• 金额: $ 1.63万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6514345
• 关键词: androgen inhibitor; bioimaging /biomedical imaging; biopsy; clinical research; diagnosis design /evaluation; gonadotropin releasing factor; hormone therapy; human subject; human therapy evaluation; magnetic resonance imaging; male; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer relapse /recurrence; nuclear magnetic resonance spectroscopy; prostate neoplasms

Androgen deprivation therapy (ADT) is being increasingly used as both a primary and neoadjuvant therapy for patients with localized prostate cancer (PCa). Our recent studies have demonstrated that the metabolic information provided by 3D MR spectroscopic imaging (MRSI) can improve the specificity of magnetic resonance imaging (MRI) in identifying prostate cancer prior to and after therapy. However, our preliminary data also indicate that the anatomic and metabolic atrophy induced by ADT is duration dependent and the ability of combined MRI/MRSI to assess the presence of residual/recurrent cancer can be reduced at certain times after therapy. Therefore, the time-course of anatomic and metabolic atrophy following hormone therapy needs to be established. Preliminary proton magic angle spinning nuclear magnetic resonance (1H MAS-NMR) spectroscopy studies of surgical specimens have also identified several metabolic changes that may further increase the specificity of MRSI for the identification of cancer after ADT. In this fellowship, serial in vivo MRI/MRSI data and 1H MAS-NMR data obtained from biopsy samples will be combined with clinical data to examine the anatomic and metabolic changes that occur in patients undergoing ADT. The goal of this work is to improve the MRI/MRSI assessment of cancer after hormone ablation and to better understand the biochemical consequences of ADT. The clinical importance of this work combined with Dr Swanson's strong interest and background in the application of NMR to biological questions and the extensive experience in MRI/MRSI of prostate that we have at UCSF makes this an ideal topic for his post-doctoral fellowship.

雄激素剥夺治疗（ADT）越来越多地用作局限性前列腺癌（PCa）患者的主要和新辅助治疗。 我们最近的研究表明，3D MR光谱成像（MRSI）提供的代谢信息可以提高磁共振成像（MRI）在治疗前后识别前列腺癌的特异性。 然而，我们的初步数据还表明，ADT诱导的解剖和代谢萎缩具有持续时间依赖性，并且在治疗后的某些时间，MRI/MRSI联合评估残留/复发癌症存在的能力可能会降低。 因此，需要确定激素治疗后解剖和代谢性萎缩的时间进程。 对手术标本进行的初步质子魔角旋转核磁共振（1H MAS-NMR）光谱学研究也发现了几种代谢变化，这些变化可能进一步增加ADT后MRSI识别癌症的特异性。 在本研究中，将从活检样本中获得的系列体内MRI/MRSI数据和1H MAS-NMR数据与临床数据相结合，以检查接受ADT的患者中发生的解剖和代谢变化。 这项工作的目标是改善激素消融后癌症的MRI/MRSI评估，并更好地了解ADT的生化后果。 这项工作的临床重要性，加上斯旺森博士对核磁共振应用于生物学问题的浓厚兴趣和背景，以及我们在加州大学旧金山分校在前列腺MRI/MRSI方面的丰富经验，使其成为他的博士后研究的理想主题。